Dr. Wang obtained his Ph.D. in Pharmaceutical Sciences with Distinction from the University of British Columbia in Vancouver in 1989 and did postdoctoral research at Wayne State University. Dr. Wang is internationally recognized for his original contributions to the field of CNS disorders-linked proteolytic enzymes. He joined Parke-Davis Pharmaceutical Research (Ann Arbor, MI) in 1991, and following the company's merger with Pfizer Inc.(2000), he became Group Leader of CNS Therapeutics and chaired the multidisciplinary CNS New targets team. He also co-chaired the Far East Scientific Opportunity Team involved in exploring values of traditional herbal medicine. He published more than 100 peer-reviewed papers, reviews and book chapters and co-authored eight US patents. He co-edited a book entitled "Calpain: the Pharmacology and Toxicology of a Calcium-dependent Protease" in 2000. He is on the Editorial Board of the journal Cell & Molecular Biology Letter and Journal of Neurotrauma. In 2002, he became Associate Professor of Psychiatry and Neuroscience at the McKnight Brian Institute of the University of Florida (Gainesville, FL). He also serves as Associate Director of the Center for Traumatic Brain Injury Studies and Director of the Center of Neuroproteomics and Biomarkers Research. In 2002, Dr. Wang co-founded Daimonion Diagnostics, LLC, which became Banyan Biomarkers Inc. (2004), an Alachua-based biotechnology company that focuses on commercialization of brain diseases and organ trauma diagnostics. In October 2007, he became full time Chief Scientific Officer and Associate Director of the Center of Innovative Research at Banyan, focusing on high quality basic science research in the field of trauma and rapid technology transfer into diagnostic and therapeutic product development.